Several drugmakers notified covered entities of changes to their 340B drug ceiling prices and national drug codes in notices posted on the Health Resources and Services Administration’s website in January and February.

Eli Lilly, Eisai, GSK and Merck Announce 340B Refunds, Other Drugmakers Report NDC Changes

March 4, 2025 Shannon Young, Associate Editor/Senior Writer Views

Several drugmakers recently notified covered entities of changes to their 340B drug ceiling prices, resulting in refunds, while others announced [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

Eli Lilly, Eisai, GSK and Merck Announce 340B Refunds, Other Drugmakers Report NDC Changes

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Shannon Young

Eli Lilly, Eisai, GSK and Merck Announce 340B Refunds, Other Drugmakers Report NDC Changes

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Shannon Young

Site Footer Live